Non-Invasive Prenatal Testing (NIPT) Market - Industry Size, Share, Growth & Forecast 2027 | UnivDatos

 

Mutations in genes and chromosomes can increase the risk of genetic abnormalities in an unborn child. The rising prevalence of chromosomal abnormalities has resulted in a surge in demand for a reliable screening tool for prenatal tests. The high risk of chromosomal abnormalities with increasing maternal age, a growing preference for non-invasive techniques over invasive methods, and an improving reimbursement scenario for NIPT are the crucial factors driving the market growth. Several established players as well as new start-ups are looking for funding to conduct research and clinical testing on NIPT techniques. Many government and private organizations are keenly looking for research institutes and start-ups for the development of innovative testing procedures to detect key genetic disorders through NIPT. For instance, in June 2019, Cradle Genomics, a San-Diego-based start-up, raised over US$ 17 Mn in Series A funding carried out to support clinical development, corporate infrastructure, CLIA lab operations, and commercial launch of the tests.

Request Sample Copy of this Report @ https://univdatos.com/get-a-free-sample-form-php/?product_id=18494

According to UnivDatos Market Insights (UMI)’ research report “Non-Invasive Prenatal Testing (NIPT) Market”, the market is expected to witness a CAGR growth of around 3.2% during the forecast period 2021-2027F. Over the last 30 years, the proportion of women conceiving at or after the age of 35 has increased significantly. This demographic shift has significant implications for women planning a pregnancy, and it may also result in a number of chromosomal abnormalities. As the percentage of pregnancies in older women has increased, so has the demand for prenatal genetic counselling.

Based on Method, the Non-Invasive Prenatal Testing (NIPT) market is categorized into Ultrasound Detection, Biochemical Screening Tests, and Cell-Free DNA in Maternal Plasma Tests. Of these three, Cell-Free DNA in Maternal Plasma Tests acquires the largest share of the Non-Invasive Prenatal Testing (NIPT) Market. The segment's rapid growth can be attributed to technological advancements and increased company initiatives to develop new products. Cell-free DNA is increasingly being used in prenatal care to predict the risk of genetic conditions using various genetic analyses. Several research studies are being conducted to advance the use of tests available through this method. For example, Togneri et al. published a study in December 2019 that implemented and validated cell-free DNA-based NIPT in the National Health Service (NHS) regional genetics laboratory. The researchers concluded that cfDNA-based NIPT can be performed as a private test in patients with a low risk of common trisomy or for other reasons.

Request Sample Copy of this Report @ https://univdatos.com/get-a-free-sample-form-php/?product_id=18494

Based on Application, the market is bifurcated into trisomy detection, microdeletion detection, and others. Among these, trisomy detection accounts for the largest share of the non-invasive prenatal testing (NIPT) market. This segment's large share and rapid growth can be attributed primarily to factors such as increasing maternal age and the rising incidence of chromosomal abnormalities. It includes birth defects, learning difficulties, and facial deformity. A child with trisomy may also have heart defects as well as vision and hearing problems. Trisomy 21, also known as Down syndrome, is one of the type of trisomy. According to the Centers for Disease Control and Prevention, the most common chromosomal condition diagnosed in the United States in 2019 is down syndrome. Every year, approximately 6,000 babies in the United States are born with Down syndrome. This means that one out of every 700 babies is born with Down syndrome. Hence, the rising incidences of down syndromes is contributing to the overall market growth.

North America Dominates the Non-Invasive Prenatal Testing (NIPT) Market

Based on regions, the report provides detailed analysis for overall demand of Non-Invasive Prenatal Testing (NIPT) for major regions including North America (US, Canada, Rest of North America); Europe (Germany, UK, France, Italy, Rest of Europe); Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific); and Rest of World.

For More Informative Information, Please Visit Us @ https://univdatos.com/report/non-invasive-prenatal-testing-nipt-market/

According to UnivDatos Market Insights (UMI)’, the key players with a considerable market share in the Non-Invasive Prenatal Testing (NIPT) Market are Illumina, Inc., Yourgene Health, Natera, F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Laboratory Corporation of America, Eurofins LifeCodex GmbH, Centogene N.V., Quest Diagnostics Incorporated, Agilent Technologies, Inc.  

“Non-Invasive Prenatal Testing (NIPT) Market” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for the market players. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitor's capabilities on different parameters. This will help companies in the formulation of go to market strategies and identifying the blue ocean for its offerings.   

Market Segmentation:

1.     By Product (Instruments {Ultrasound Devices, Next-Generation Sequencing Systems, Polymerase Chain Reaction Instruments, Microarrays, Others}, Consumables {Assay Kits & Reagents, Disposables})

2.     By Method (Ultrasound Detection, Biochemical Screening Tests, Cell-Free DNA in Maternal Plasma Tests)

3.     By Application (Trisomy Detection, Microdeletion Detection, Others)

4.     By End-User (Hospitals & Clinics, Diagnostic Laboratories, Others)

5.     By Region (North America, Europe, Asia-Pacific, Rest of World)

6.     By Company (Illumina, Inc., Yourgene Health, Natera, F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Laboratory Corporation of America, Eurofins LifeCodex

7.      GmbH, Centogene N.V., Quest Diagnostics Incorporated, Agilent Technologies, Inc.)

Key questions answered in the study:

1.     What are the current and future trends of the Non-Invasive Prenatal Testing (NIPT) industry?

2.     How the industry has been evolving in terms of distribution channel and product category?

3.     How the competition has been shaping across the countries followed by their comparative factorial indexing?

4.     What are the key growth drivers and challenges for the Non-Invasive Prenatal Testing (NIPT) industry?

5.     What is the customer orientation, purchase behavior, and expectations from the Non-Invasive Prenatal Testing (NIPT) product suppliers across various countries?

Table of Content –

1 MARKET INTRODUCTION

2 RESEARCH METHODOLOGY OR ASSUMPTION

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 NON-INVASIVE PRENATAL TESTING (NIPT) MARKET COVID-19 IMPACT

6 INTELLIGENT LIGHTING CONTROLS MARKET REVENUE (USD BN), 2019-2027F

7 MARKET INSIGHTS BY CONNECTIVITY TYPE

8 MARKET INSIGHTS BY METHOD

9 MARKET INSIGHTS BY APPLICATION

10 MARKET INSIGHTS BY END-USER

11 MARKET INSIGHTS BY REGION

12 NON-INVASIVE PRENATAL TESTING (NIPT)MARKET DYNAMICS

13 NON-INVASIVE PRENATAL TESTING (NIPT) MARKET OPPORTUNITIES

14 NON-INVASIVE PRENATAL TESTING (NIPT) MARKET TRENDS

15 LEGAL & REGULATORY FRAMEWORK

16 DEMAND AND SUPPLY SIDE ANALYSIS

17 COMPETITIVE SCENARIO

18 COMPANY PROFILED

19 DISCLAIMER

Browse Other Related Research Reports from UnivDatos Market Insights

·       Mobile Health Application (mHealth Apps) Market to Reach US$ 315.4 Billion by 2027, Globally |CAGR: 44.4%

·       Nanotechnology in Drug Delivery Market to Reach US$ 182.3 Billion by 2027, Globally | CAGR: 19.9% | 

·       Healthcare Chatbot Market to Reach US$ 967.7 Million by 2027, Globally |CAGR: 21.56%|

·       Kyphoplasty Market to Reach US$ 3.2 Billion by 2027 Globally | CAGR: 14.5% |